Literature DB >> 24694487

Corticosteroid therapy was effective in controlling refractory coronary vasospasms complicated by hypereosinophilia.

Tetsuya Nomura1, Natsuya Keira, Shunta Taminishi, Hiroshi Kubota, Yusuke Higuchi, Sho Ikegame, Kensuke Terada, Taku Kato, Yota Urakabe, Tetsuya Tatsumi.   

Abstract

A 48-year-old man suffered from uncontrollable coronary vasospasms, even when taking the maximum dose of vasodilators. The patient had a history of hypereosinophilia, and as the eosinophilia worsened, more frequent and intense coronary spastic angina (CSA) attacks occurred. He was treated with 20 mg/day of oral prednisolone, and the chest symptoms of CSA completely resolved thereafter. We encountered a refractory CSA patient with an allergic predisposition for which the oral administration of corticosteroids was markedly effective. Although the priority of corticosteroid therapy is not clinically high in patients with CSA, it can be effective especially in patients with an allergic background.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 24694487     DOI: 10.2169/internalmedicine.53.1639

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Coronary artery vasospasm and cardiogenic shock as the initial presentation for eosinophilic granulomatosis with polyangiitis.

Authors:  Abdallah Y Bitar; Caleb D Thompson; Christina W Tan; Kavitta Allem; Aelita Khachatrian; Peter J Weis; Vikram Garg; Ajay Srivastava
Journal:  J Cardiol Cases       Date:  2015-12-29

2.  Efficacy of Corticosteroid Treatment for Refractory Multivessel Vasospastic Coronary Angina with Hypereosinophilia.

Authors:  Toshiki Takano; Kazuyuki Ozaki; Komei Tanaka; Takao Yanagawa; Takuya Ozawa; Tohru Minamino
Journal:  Intern Med       Date:  2018-06-06       Impact factor: 1.271

3.  Coronary Spastic Angina Induced by Adrenal Insufficiency.

Authors:  Yuki Otsuka; Ko Harada; Miho Yasuda; Yasuhiro Nakano; Kou Hasegawa; Fumio Otsuka
Journal:  Intern Med       Date:  2020-04-30       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.